Intuitive Surgical (ISRG) is heading into a period of intensifying competitive headwinds and long-term pricing pressure, Oppenheimer said Friday in a report.
Intuitive's scarcity-value premium is increasingly difficult to defend, Oppenheimer said, highlighting unsustainable pricing dynamics and growing threats from emerging Chinese robotic systems as key constraints on the company's forward growth profile.
US procedure volumes slowed in Q2, rising 12% from a year earlier versus 14% in Q1, a trend only partly explained by Affordable Care Act-related patient deferrals, the report said. Despite the softer quarter, Intuitive maintained its 2026 procedure growth outlook of 13.5% to 15.5%, implying 14% growth in H2, Oppenheimer said.
The guidance incorporates ACA premium shifts, new obesity drugs, competitive pressure from Chinese platforms, and capital-spending constraints in Japan and Europe, the report said. Oppenheimer also noted that Intuitive's move toward extended-use instruments may weigh on instruments and accessories growth in 2027, Oppenheimer said.
Oppenheimer has a perform rating on Intuitive Surgical. At least 12 other analysts cut their price targets on the stock following the Q2 results.
Price: $355.39, Change: $-46.94, Percent Change: -11.67%